TIZIMLI QIZIL YUGURIKNI DAVOLASHNING ZAMONAVIY  STRATEGIYASI: EULAR 2023 VA ACR 2025 TAVSIYALARI ASOSIDA

Sapayeva Sharofat; Islomov Inomjon; Xudoyberdiyev Muzaffar; Pulatova Ma`mura

Vol. 3 No. 8 (2026), Articles

Vol. 3 No. 8 (2026)

TIZIMLI QIZIL YUGURIKNI DAVOLASHNING ZAMONAVIY STRATEGIYASI: EULAR 2023 VA ACR 2025 TAVSIYALARI ASOSIDA

Articles

Published 2026-09-03

Sapayeva Sharofat ⁺⁻
Islomov Inomjon⁺⁻
Xudoyberdiyev Muzaffar ⁺⁻
Pulatova Ma`mura⁺⁻

Sapayeva Sharofat

Urganch davlat tibbiyot instituti

Islomov Inomjon

Kardiolog

Xudoyberdiyev Muzaffar

Terapevt

Pulatova Ma`mura

Urganch davlat tibbiyot instituti, terapiya (ichki kasalliklar) yo`nalishi 2-kurs klinik ordinatori.

PDF

DOI

Keywords

tizimli qizil yugurik, TQY, remissiya, past kasallik faolligi, gidroksixloroxin, glyukokortikoid, immunosupressiv terapiya.

How to Cite

TIZIMLI QIZIL YUGURIKNI DAVOLASHNING ZAMONAVIY STRATEGIYASI: EULAR 2023 VA ACR 2025 TAVSIYALARI ASOSIDA . (2026). FAN, TA’LIM, TEXNOLOGIYA VA ISHLAB CHIQARISH INTEGRATSIYASI ASOSIDA RIVOJLANISH ISTIQBOLLARI, 3(8), 32-35. https://universalpublishings.com/index.php/fan/article/view/20488

Abstract

Tizimli qizil yugurik (TQY) - immunologik tolerantlikning buzilishi, autoantitanachalar va immun komplekslar hosil bo`lishi bilan kechadigan, turli organ va tizimlarni zararlashi bilan kechuvchi surunkali autoimmun kasallikdir. TQYda uzoq muddatli prognoz kasallik faolligi, qaytalanuvchi zo`rayishlar, qaytmas organ shikastlanishi hamda davolash bilan bog`liq toksiklik bilan belgilanadi. Zamonaviy davolashning asosiy maqsadi remissiya yoki past kasallik faolligiga erishish, organ shikastlanishi oldini olish va glyukokortikoidlar ekspozitsiyasini imkon qadar kamaytirishdan iborat.

PDF

DOI

References

1. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29.DOI: 10.1136/ard-2023-224762.

2. Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026;78(7):1161-1386. DOI: 10.1002/art.43452

3. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol. 2025;77(9): 1115-1135. DOI: 10.1002/art.43212.

4. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. DOI:10.1002/art.40930.